SUBSCRIBE
SUBSCRIBE

Biogen

NEWS
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Investors Cheer As Biogen’s BIIB037 Skips To Phase 3 For Alzheimer’s
December 3, 2014
 · 
1 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Genetown
FDA Warning: PML Death Associated With Biogen Idec’s Tecfidera
November 26, 2014
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Genetown
Biogen Idec Slumps After Patient On Top-Selling Drug Dies
October 23, 2014
 · 
2 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Deals
Largest Biotech IPO Yet Could Be Derailed By Forward Pharma, Biogen Idec Patent Fight
October 15, 2014
 · 
1 min read
Genetown
5 Boston Biotechs Whose Revenue Is Growing Faster Than Biogen Idec, Inc. (Massachusetts)'s
October 3, 2014
 · 
1 min read
Analysts Not Sold On Medivation’s Xtandi as Breast Cancer Drug
Genetown
Analysts Say Biogen Idec, Inc. (Massachusetts) Must Push Into Gene Therapy To Stay Competitive
September 23, 2014
 · 
1 min read
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Genetown
Biogen Idec, Inc. (Massachusetts) Suddenly Struggling To Keep Up With The Biotech Joneses
September 12, 2014
 · 
1 min read
Here’s Why 5 Billionaire-Led Funds Gobbled Up 3.3 Million Shares of Celldex Stock
Business
Novartis AG Follows Biogen Idec, Inc. (Massachusetts), GlaxoSmithKline’s Footsteps With New State Of The Art Offices; Space Reflects “The Novartis Way Of Working”
August 29, 2014
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Biogen Idec, Inc. (Massachusetts) Poaches Renowned Neurologist From Novartis AG To Lead ALS Innovation Hub
August 26, 2014
 · 
2 min read
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
May 22, 2026
 · 
15 min read
Press Releases
The ADDF Highlights Encouraging Progress Toward Targeting Multiple Alzheimer’s Pathologies in Biogen’s Phase 2 Tau Study
May 14, 2026
 · 
3 min read
Press Releases
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
May 14, 2026
 · 
8 min read
Press Releases
Biogen Completes Acquisition of Apellis Pharmaceuticals
May 14, 2026
 · 
21 min read
Press Releases
Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease
May 14, 2026
 · 
11 min read
Press Releases
Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer’s Disease
May 8, 2026
 · 
18 min read
Press Releases
Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region
April 20, 2026
 · 
14 min read
Press Releases
Eisai to Present the Latest Data on Real-World Treatment with Lecanemab and Supporting a Standardized Framework for Treating Early Alzheimer’s Disease at the 78th American Academy of Neurology’s Annual Meeting
April 9, 2026
 · 
10 min read
Press Releases
Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy’s AntiClastic™ ASO Platform
April 7, 2026
 · 
3 min read
Press Releases
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
March 31, 2026
 · 
32 min read
Load More